Cytos exclusively licenses its VLP platform for the treatment of hepatitis B infections to OnCore Biopharma
Cytos Biotechnology Ltd. announced that it executed an exclusive license agreement granting OnCore Biopharma, Inc. access to Cytos’ clinically validated virus like particle (VLP) platform for the use in the treatment and prevention of hepatitis B viral infections. Cytos also granted an option for the treatment of additional viral diseases other than influenza. The agreement will become effective with the achievement of certain closing conditions, including a successful debt restructuring of Cytos.
For the first product in each of six possible product categories in the field of Hepatitis B that may be developed under the agreement, Cytos may receive up to USD 67 million in development milestones, or a maximum of USD 402 million if one product in each product category is developed. In addition, Cytos is eligible to receive commercial milestone payments of up to USD 120 million upon achievement of certain sales levels, and up to double-digit royalties on net sales from any successfully developed product.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.